Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Potential applications<br />
ANGIOSTOP has both strategic and specifi c deliverables and<br />
milestones. The new animal models and acquired know ledge<br />
on pathologic and therapeutic angiogenesis will transcend<br />
the specifi c aims of the drug development programs and be<br />
of strategic signifi cance for angiogenesis research in general.<br />
The translational and critical path research program has<br />
a clearly defi ned ultimate deliverable: a new medicine based<br />
on PlGF-neutralizing antibody for anti-angiogenic treatment<br />
of certain solid tumours, ocular diseases and arthritis.<br />
ANGIOSTOP is exploring the therapeutic potential and pleiotropic mechanism of anti-PlGF,<br />
antibodies against placental growth factor (PlGF), a VEGF homologue, which regulates the<br />
angiogenic switch in disease but not in health. Anti-PlGF antibodies inhibit tumour growth by<br />
blocking angiogenesis. Distinct from VEGF inhibitors, however, targeting PlGF has been found<br />
to prevent infi ltration of angiogenic macrophages, and thus do not switch on the angiogenic<br />
rescue program responsible for resistance to VEGF inhibitors. This mechanism is illustrated with<br />
anti-PlGF (depicted in blue) preventing PlGF (green) binding to its receptor VEGFR-1+ (red)<br />
expressed on macrophages (orange).<br />
TREATMENT<br />
Coordinator<br />
Titti Martinsson-Niskanen<br />
BioInvent International AB<br />
Lund, Sweden<br />
titti.martinsson.niskanen@bioinvent.com<br />
Partners<br />
Jean-Marie Stassen<br />
ThromboGenics Ltd<br />
Leuven, Belgium<br />
jmstassen@thrombogenics.com<br />
Peter Carmeliet<br />
Flanders Interuniversity Institute<br />
for Biotechnology VZW<br />
Leuven, Belgium<br />
peter.carmeliet@med.kuleuven.be<br />
Project number<br />
LSHB-CT-2006-037386<br />
EC contribution<br />
€ 1 993 208<br />
Duration<br />
28 months<br />
Starting date<br />
01/06/2006<br />
Instrument<br />
SME-STREP<br />
Christian Fischer<br />
Charité Universitaetsmedizin Berlin<br />
Berlin, Germany<br />
christian.fischer@med.kuleuven.be<br />
Eric Van Cutsem<br />
Katholieke Universiteit Leuven<br />
Leuven, Belgium<br />
eric.vancutsem@uz.kuleuven.ac.be<br />
Wen Jiang<br />
Cardiff University<br />
Cardiff, United Kingdom<br />
jiangw@Cardiff.ac.uk<br />
165
Change language